Purpose Individuals with recurrent breast malignancy usually die of their disease, even after radical surgery and adjuvant treatments which could reduce the odds of dying. Results Histologic grade (p=0.005), nuclear grade (p<0.001), p53 (p=0.022), and Ki-67 (p<0.001) were significant different factors that influenced the systemic recurrence between early recurrence and late recurrence. In stage I/II, histologic grade (p=0.001), nuclear grade (p<0.001), and Ki-67 (p=0.005) were significant factors that influenced the systemic early recurrence. In stage III, nuclear grade (p=0.024), and Ki-67 (p=0.001) were significant factors that influenced the systemic early recurrence. But subtypes (p=0.189, p=0.132, p=0.593, p=0.083) are not associated with the timing of recur rence. Summary In systemic recurrent breast cancer individuals, the risk factors such as histologic grade, nuclear grade, p53 and Ki-67 will also be associated with the timing of recurrence. We sug gest that these individuals should be appropriate treated and be closely adopted up. LDN193189 HCl class=”kwd-title”>Keywords: Breast neoplasms, Recurrence, Risk factors INTRODUCTION According to the Annual Statement of Korea Central Malignancy Registry in 2009 2009 the number of breast malignancy occurrences for women’s in Korea in 2007 is definitely 15.1%, the second highest one next to thyroid malignancy . Recently the treatment outcome of breast cancer has been improved owing to the development in curative surgery, chemotherapy and endocrine therapy; however, about 25% to 30% of the individuals having no axillary lymph node metastasis and about 75% LDN193189 HCl to 80% of the individuals having axillary lymph node metastasis encounter recurrence in 10 years, and most of them die due to the metastatic breast malignancy [2,3]. As a result, studies within the factors that influence prognosis have been completed. The factors known up to now are the axillary lymph node metastasis, tumor’s size, the histologic type and differentiation degree of tumors, the receptors of estrogen and progesterone, and overexpression of the genes p53 and c-erbB-2 . However, these studies focused on comparing the individuals who died due to recurrences and the individuals who have been alive, and they have not evaluated the important indexes which have relationship with recurrence period, though 70% of the breast cancer individuals encounter recurrences in 3 years [5,6] and individuals with early recurrence encounter a shorter median survival than individuals with late recurrence . With this context, this study was performed to evaluate the factors influencing recurrence period in the instances of the individuals who experienced recurrence after 1st treatment of breast cancer. METHODS Subject The 95 instances of metastatic breast cancer LDN193189 HCl individuals who experienced systemic recurrences experienced LCN1 antibody curative surgeries in the Breast Cancer Medical center of Gachon University or college Gill Hospital between January 2002 to December 2008. This study was authorized by the Institutional Review Table of Gachon University or college Gil Hospital (GIRBA 2769-2012). Methods We evaluated retrogressively the recurrence features in regard to patient’s age, menopausal timing, method of surgery treatment, stage, nodal status, histologic differentiation, living of estrogen receptor, living of progesterone receptor, living of an extensive intraductal carcinoma component (EIC), living of overexpression of genes p53 and c-erbB-2, expression degree of Ki-67, molecular subtype (luminal A type, luminal B type, HER2 positive type, triple bad type) and the supplementary treating such as chemotherapy, radiation therapy or endocrine therapy after curative surgery. We evaluated the factors influencing the recurrence period for the individuals who experienced recurrence after the 1st treatment of breast malignancy by classifying them into two organizations; the first group of early recurrence in which they had the recurrence before 2 years from the completion of curative surgery and chemotherapy and the second group of past due recurrence in which they had the recurrence after 2 years from the completion of treatment. Because 70% of breast cancer individuals encounter recurrences within 3 years, we used these criteria and some of these individuals were done with radiation therapy as well as others LDN193189 HCl were with endocrine therapy when needed. The data were processed with SPSS version 18.0 (SPSS Inc., Chicago, USA). The correlation between each clinopathologic element and recurrent period was analyzed with chi-square test. And for the analysis of statistical significance of individual distribution between the organizations nonparametric chi-square test was used. A p-value <0.05 was considered as statistically significant. RESULTS General characteristics of individuals The average period LDN193189 HCl of monitoring of the individuals is definitely 53.5 months (range, 6.4-116.5 months). The general characteristics of individuals are offered in Table 1. Each individual was that was classified relating to nodal status and stage. After curative surgery, chemotherapy and radiation therapy and endocrine therapy were carried out as supplementary treating. For chemotherapy all individuals received chemotherapy and lymph node bad breast malignancy individuals received adjuvant systemic treatment with cyclophosphamide, methotrexate, 5-fluorouracil.